Inactive Instrument

ArQule, Inc.

Equities

US04269E1073

Biotechnology & Medical Research

Arqule Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 01, 2019 at 07:31 am EDT

ArQule Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced operating loss was USD 10.403 million compared to USD 4.025 million a year ago. Net loss was USD 10.267 million compared to USD 6.532 million a year ago. Basic loss per share was USD 0.09 compared to USD 0.07 a year ago.

Latest news about ArQule, Inc.

ArQule, Inc. Announces Management Changes	20-01-16	CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P TMI Index	20-01-16	CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Biotechnology Select Industry Index	20-01-16	CI
ArQule, Inc.(NasdaqGM:ARQL) dropped from S&P Global BMI Index	20-01-16	CI
Merck Sharp & Dohme Corp. completed the acquisition of ArQule, Inc..	20-01-14	CI
Wall St. falls as Apple, health shares drag, tariff deadline looms	19-12-09	RE
Transcript : ArQule, Inc. - Special Call	19-12-09
ArQule, Inc. Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	19-12-09	CI
Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire ArQule, Inc. for $2.4 billion.	19-12-08	CI
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting	19-11-25	CI
ArQule, Inc. Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies	19-11-06	CI
Transcript : ArQule, Inc., Q3 2019 Earnings Call, Oct 30, 2019	19-10-30
ArQule, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-30	CI
ArQule, Inc. Provides Financial Guidance for 2019	19-10-30	CI
ArQule, Inc. Presents Recent Data on ARQ 751	19-10-29	CI
ArQule Announces Preclinical Data Demonstrating Potential of Miransertib (ARQ 092) to Treat PIK3CA-Driven Vascular Malformations at 2019 ASHG Annual Meeting	19-10-21	CI
ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	19-10-16	CI
ArQule, Inc. Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum	19-10-02	CI
Certain Common Stock of ArQule, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2019.	19-09-22	CI
Certain Warrants of ArQule, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2019.	19-09-22	CI
Certain Options of ArQule, Inc. are subject to a Lock-Up Agreement Ending on 23-SEP-2019.	19-09-22	CI
Transcript : ArQule, Inc. Presents at Citi's 14th Annual Biotech Conference, Sep-04-2019 03:00 PM	19-09-04
Transcript : ArQule, Inc., Q2 2019 Earnings Call, Aug 07, 2019	19-08-07
ArQule, Inc. Provides Financial Guidance for the Fiscal Year 2019	19-08-07	CI
Arqule, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-07	CI

Chart ArQule, Inc.

Duration

Period

More charts

Company Profile

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+41.79%	50.93B
IQVIA HOLDINGS INC.	-0.56%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	18.9B
BIO-TECHNE CORPORATION	+6.92%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.17B
MEDPACE HOLDINGS, INC.	+29.60%	12.16B

Other Biotechnology & Medical Research